Early Improvement in One Week Predicts the Treatment Response to Escitalopram in Patients with Social Anxiety Disorder: A Preliminary Study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Objective: Social anxiety disorder (SAD) shows relatively delayed responses to pharmacotherapy when compared to other anxiety disorders. Therefore, more effective early therapeutic decisions can be made if the therapeutic response is predictable as early as possible. We studied whether the therapeutic response at 12 weeks is predictable based on the early improvement with escitalopram at 1 week. Methods: The subjects were 28 outpatients diagnosed with SAD. The subjects took 10-20 mg/day of escitalopram. The results of the Liebowitz social anxiety scale (LSAS), Hamilton anxiety rating scale, and Montgomery-Asberg depression rating scale were evaluated at 0, 1, 4, 8, and 12 weeks of treatment. Early improvement was defined as a ≥10% reduction in the LSAS total at 1 week of treatment, and endpoint response was defined as a ≥35% reduction in the LSAS total score. The correlation between clinical characteristics and therapeutic responses was analyzed by simple linear regression. The correlation between early improvement responses and endpoint responses was analyzed by multivariate logistic regression analysis and receiver operating characteristic curves. Results: When we adjusted the influence of a ≥35% reduction in the LSAS total endpoint score on a ≥10% reduction of the LSAS total score at 1 week of treatment for the patients’ age, the early improvement group at 1 week of treatment was expected to show stronger endpoint responses compared to the group with no early improvement. Conclusion: The results suggest that a ≥10% reduction in the LSAS total score in a week can predict endpoint treatment response.
Abstract
Objective: Social anxiety disorder (SAD) shows relatively delayed responses to pharmacotherapy when compared to other anxiety disorders. Therefore, more effective early therapeutic decisions can be made if the therapeutic response is predictable as early as possible. We studied whether the therapeutic response at 12 weeks is predictable based on the early improvement with escitalopram at 1 week. Methods: The subjects were 28 outpatients diagnosed with SAD. The subjects took 10-20 mg/day of escitalopram. The results of the Liebowitz social anxiety scale (LSAS), Hamilton anxiety rating scale, and Montgomery-Asberg depression rating scale were evaluated at 0, 1, 4, 8, and 12 weeks of treatment. Early improvement was defined as a ≥10% reduction in the LSAS total at 1 week of treatment, and endpoint response was defined as a ≥35% reduction in the LSAS total score. The correlation between clinical characteristics and therapeutic responses was analyzed by simple linear regression. The correlation between early improvement responses and endpoint responses was analyzed by multivariate logistic regression analysis and receiver operating characteristic curves. Results: When we adjusted the influence of a ≥35% reduction in the LSAS total endpoint score on a ≥10% reduction of the LSAS total score at 1 week of treatment for the patients’ age, the early improvement group at 1 week of treatment was expected to show stronger endpoint responses compared to the group with no early improvement. Conclusion: The results suggest that a ≥10% reduction in the LSAS total score in a week can predict endpoint treatment response.
참고문헌 (39)
- Kessler RC, "Social phobia subtypes in the National Comorbidity Survey", Am J Psychiatry, 155, pp.613~619 (1998)
- Kessler RC, "Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 62, pp.593~602 (2005)
- Schneier FR, "Social phobia. Comorbidity and morbidity in an epidemiologic sample", Arch Gen Psychiatry, 49, pp.282~288 (1992)
- Blanco C, "The evidence-based pharmacological treatment of social anxiety disorder", Int J Neuropsychopharmacol, 6, pp.427~442 (2003)
- Lydiard RB, "Therapeutic advances: paroxetine for the treatment of social anxiety disorder", Depress Anxiety, 11, pp.99~104 (2000)
- Stein MB, "Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation", J Clin Psychopharmacol, 16, pp.218~222 (1996)
- Stein MB, "Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study", Am J Psychiatry, 156, pp.756~760 (1999)
- Van Ameringen MA, "Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebocontrolled study", Am J Psychiatry, 158, pp.275~281 (2001)
- Varia IM, "Treatment of social anxiety disorder with citalopram", Prog Neuropsychopharmacol Biol Psychiatry, 26, pp.205~208 (2002)
- Bandelow B, "What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?", J Clin Psychiatry, 67, pp.1428~1434 (2006)
- Versiani M, "Social phobia:long-term treatment outcome and prediction of response--a moclobemide study", Int Clin Psychopharmacol, 12, pp.239~254 (1997)
- Chambless DL, "Predictors of response to cognitive-behavioral group therapy for social phobia", J Anxiety Disord, 11, pp.221~240 (1997)
- Pande AC, "Treatment of social phobia with gabapentin: a placebo-controlled study", J Clin Psychopharmacol, 19, pp.341~348 (1999)
- Slaap BR, "Responders and non-responders to drug treatment in social phobia: differences at baseline and prediction of response", J Affect Disord, 39, pp.13~19 (1996)
- Montgomery SA, "Implications of the severity of social phobia", J Affect Disord, 50(Suppl 1), pp.S17~S22 (1998)
- Stein DJ, "Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials", J Clin Psychiatry, 63, pp.152~155 (2002)
- Van Ameringen M, "Predictors of response in generalized social phobia: effect of age of onset", J Clin Psychopharmacol, 24, pp.42~48 (2004)
- Pollack MH, "Early improvement during duloxetine treatment of generalized anxiety disorder predicts response and remission at endpoint", J Psychiatr Res, 42, pp.1176~1184 (2008)
- Baldwin DS, "Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR?", Eur Neuropsychopharmacol, 22, pp.137~142 (2012)
- American Psychiatric Association, "Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders:DSM-IV", American Psychiatric Association, ~ (1994)
- Lecrubier Y, "The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview:reliability and validity according to the CIDI", European Psychiatry, 12, pp.224~231 (1997)
- Williams JB, "A structured interview guide for the Hamilton Depression Rating Scale", Arch Gen Psychiatry, 45, pp.742~747 (1988)
- 유은승, "한국판 Liebowitz사회불안척도(LSAS)의 요인구조 및 진단적 유용성 -대학생 집단과 사회공포증환자 집단을 중심으로", Korean Journal of Clinical Psychology, 26(1), pp.251~270 (2007), 한국임상심리학회
- Shear MK, "Reliability and validity of a structured interview guide for the Hamilton Anxiety Rating Scale (SIGH-A)", Depress Anxiety, 13, pp.166~178 (2001)
- 안용민, "한글판 Montgomery-Åsberg 우울증 평가 척도의 표준화 연구", 신경정신의학, 44(4), pp.466~476 (2005), 대한신경정신의학회
- Metz CE, "Basic principles of ROC analysis", Semin Nucl Med, 8, pp.283~298 (1978)
- Pollack MH, "Early improvement predicts endpoint remission status in sertraline and placebo treatments of panic disorder", J Psychiatr Res, 36, pp.229~236 (2002)
- van Vliet IM, "Psychopharmacological treatment of social phobia; a double blind placebo controlled study with fluvoxamine", Psychopharmacology (Berl), 115, pp.128~134 (1994)
- Stein MB, "Subtypes of social phobia and comorbidity with depression and other anxiety disorders", J Affect Disord, 50(Suppl 1), pp.S11~S16 (1998)
- Stahl SM, "Stahl's essential psychopharmacology: neuroscientific basis and practical applications" (2013), Cambridge University Press
- Wehrenberg M, "The anxious brain: the neurobiological basis of anxiety disorders and how to effectively treat them" (2007), W.W. Norton & Co
- Boone ML, "Multimodal comparisons of social phobia subtypes and avoidant personality disorder", J Anxiety Disord, 13, pp.271~292 (1999)
- Levin AP, "Responses of “generalized” and “discrete”social phobics during public speaking", J Anxiety Disord, 7, pp.207~221 (1993)
- Scholing A, "Prediction of treatment outcome in social phobia: a cross-validation", Behav Res Ther, 37, pp.659~670 (1999)
- Taylor MJ, "Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis", Arch Gen Psychiatry, 63, pp.1217~1223 (2006)
- Rynn M, "Early response and 8-week treatment outcome in GAD", Depress Anxiety, 23, pp.461~465 (2006)
- Liebowitz MR, "A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder", J Clin Psychiatry, 63, pp.66~74 (2002)
- Liebowitz MR, "A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder", J Clin Psychiatry, 66, pp.238~247 (2005)
- Pallanti S, "Resistant social anxiety disorder response to Escitalopram", Clin Pract Epidemiol Ment Health, 2, pp.35~ (2006)